CO7101244A2 - Fenilimidazopirazoles sustituidos y su uso - Google Patents

Fenilimidazopirazoles sustituidos y su uso

Info

Publication number
CO7101244A2
CO7101244A2 CO14162331A CO14162331A CO7101244A2 CO 7101244 A2 CO7101244 A2 CO 7101244A2 CO 14162331 A CO14162331 A CO 14162331A CO 14162331 A CO14162331 A CO 14162331A CO 7101244 A2 CO7101244 A2 CO 7101244A2
Authority
CO
Colombia
Prior art keywords
diseases
phenylimidazopyrazoles
substituted
prevention
preparation
Prior art date
Application number
CO14162331A
Other languages
English (en)
Spanish (es)
Inventor
Frank Submeier
Mario Lobell
Sylvia Grunewald
Michael Harter
Bernd Buchmann
Joachim Telser
Hannah Joriben
Melanie Heroult
Antje Kahnert
Klemens Lustig
Niels Lindner
Original Assignee
Bayer Pharma AG
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47594775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7101244(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG, Bayer Ip Gmbh filed Critical Bayer Pharma AG
Publication of CO7101244A2 publication Critical patent/CO7101244A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CO14162331A 2012-01-25 2014-07-25 Fenilimidazopirazoles sustituidos y su uso CO7101244A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12152515 2012-01-25

Publications (1)

Publication Number Publication Date
CO7101244A2 true CO7101244A2 (es) 2014-10-31

Family

ID=47594775

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14162331A CO7101244A2 (es) 2012-01-25 2014-07-25 Fenilimidazopirazoles sustituidos y su uso

Country Status (30)

Country Link
US (2) US20150005288A1 (enExample)
EP (1) EP2807162B1 (enExample)
JP (1) JP6101290B2 (enExample)
KR (1) KR20140117582A (enExample)
CN (1) CN104411707B (enExample)
AP (1) AP2014007869A0 (enExample)
AR (1) AR089788A1 (enExample)
AU (1) AU2013211707A1 (enExample)
BR (1) BR112014018450A8 (enExample)
CA (1) CA2862163A1 (enExample)
CL (1) CL2014001959A1 (enExample)
CO (1) CO7101244A2 (enExample)
CR (1) CR20140362A (enExample)
CU (1) CU20140096A7 (enExample)
DO (1) DOP2014000173A (enExample)
EA (1) EA201491427A1 (enExample)
EC (1) ECSP14010868A (enExample)
ES (1) ES2639338T3 (enExample)
GT (1) GT201400161A (enExample)
IL (1) IL233652A0 (enExample)
MA (1) MA35877B1 (enExample)
MX (1) MX2014008893A (enExample)
PE (1) PE20142421A1 (enExample)
PH (1) PH12014501687A1 (enExample)
SG (1) SG11201404118XA (enExample)
TN (1) TN2014000320A1 (enExample)
TW (1) TW201343649A (enExample)
UY (1) UY34590A (enExample)
WO (1) WO2013110590A1 (enExample)
ZA (1) ZA201405392B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2862163A1 (en) * 2012-01-25 2013-08-01 Bayer Pharma Aktiengesellschaft Substituted phenylimidazopyrazoles and use thereof
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
US20180368404A1 (en) 2014-11-06 2018-12-27 Basf Se 3-pyridyl heterobicyclic compound for controlling invertebrate pests
BR112018007034B1 (pt) * 2015-10-08 2022-10-11 Fmc Corporation Composto, composição, método para controlar uma praga de invertebrados e semente revestida
PY1974629A (es) * 2018-09-13 2021-01-11 Syngenta Participations Ag Compuestos de azol-amida pesticidamente activos
CN109096195A (zh) * 2018-09-27 2018-12-28 上海雅本化学有限公司 一种艾曲波帕的制备方法
KR20220082835A (ko) * 2019-10-16 2022-06-17 바이엘 악티엔게젤샤프트 1,1'-디술판디일비스(4-플루오로-2-메틸-5-니트로벤졸)의 제조 방법
BR112022015110A2 (pt) * 2020-01-29 2022-11-08 Foghorn Therapeutics Inc Compostos e usos dos mesmos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753730B2 (ja) * 1988-07-26 1995-06-07 三共株式会社 イミダゾピラゾール誘導体
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
KR101061599B1 (ko) * 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
CA2765534C (en) * 2009-06-15 2018-09-18 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
KR101116756B1 (ko) * 2009-10-27 2012-03-13 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 신규의 1,6-치환된 인돌 화합물
CA2862163A1 (en) * 2012-01-25 2013-08-01 Bayer Pharma Aktiengesellschaft Substituted phenylimidazopyrazoles and use thereof

Also Published As

Publication number Publication date
WO2013110590A1 (de) 2013-08-01
GT201400161A (es) 2015-03-05
IL233652A0 (en) 2014-08-31
SG11201404118XA (en) 2014-10-30
ZA201405392B (en) 2015-12-23
US20130190290A1 (en) 2013-07-25
EP2807162B1 (de) 2017-06-07
ECSP14010868A (es) 2015-12-31
CA2862163A1 (en) 2013-08-01
EA201491427A1 (ru) 2015-01-30
TN2014000320A1 (en) 2015-12-21
US20150005288A1 (en) 2015-01-01
UY34590A (es) 2013-09-02
CL2014001959A1 (es) 2014-11-07
DOP2014000173A (es) 2014-08-31
CR20140362A (es) 2014-08-21
TW201343649A (zh) 2013-11-01
MA35877B1 (fr) 2014-12-01
EP2807162A1 (de) 2014-12-03
BR112014018450A8 (pt) 2017-07-11
AU2013211707A1 (en) 2014-08-07
PE20142421A1 (es) 2015-01-11
CU20140096A7 (es) 2015-02-26
JP6101290B2 (ja) 2017-03-22
KR20140117582A (ko) 2014-10-07
PH12014501687A1 (en) 2014-10-20
AP2014007869A0 (en) 2014-08-31
US9394309B2 (en) 2016-07-19
BR112014018450A2 (enExample) 2017-06-20
HK1203198A1 (en) 2015-10-23
MX2014008893A (es) 2014-08-26
JP2015504904A (ja) 2015-02-16
CN104411707A (zh) 2015-03-11
CN104411707B (zh) 2017-03-01
AR089788A1 (es) 2014-09-17
ES2639338T3 (es) 2017-10-26

Similar Documents

Publication Publication Date Title
CU20140096A7 (es) Fenilimidazopirazoles sustituidos y su uso
MX2019010601A (es) Terapia de combinacion para tratar cancer.
CR20120596A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
MX373187B (es) Terapia de combinación para tratar cáncer.
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
MX380273B (es) Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp.
NI201400104A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
BR112013027119A8 (pt) novos conjugados ligante-droga (adcs) e uso dos mesmos
UY32237A (es) Compuestos de arilo con sustituyentes heterociclicos y su uso
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
UY35115A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
AR089252A1 (es) Conjugados de principio activo-ligante (adc) y su uso
UY35652A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
CR20140513A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
UY32236A (es) Compuestos de arilo sustituidos y su uso
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
BR112015006363A2 (pt) combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
UY36408A (es) Derivados de pirido benzodiazepina sustituidos y su utilización
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila